Clinical Study on Dachai-Wendan Decoction in Treating Metabolic Syndrome Caused by Atypical Antipsychotics

Beijing Huilongguan Hospital0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Subjects who met the ICD-10 diagnostic criteria for schizophrenia;
•2. Patients who met the diagnostic criteria of metabolic syndrome in Chinese guidelines for the prevention and treatment of type 2 diabetes (2017 Edition):
•(1) Abdominal obesity (central obesity): waist circumference of male >= 90 cm, female >= 85 cm;
•(2) Hyperglycemia: fasting blood glucose >= 6.1 mmol / L or blood glucose >= 7.8 mmol / L 2 h after glucose load and / or diabetes mellitus diagnosed and treated;
•(3) Hypertension: blood pressure >= 130 / 85 mmHg and / or confirmed hypertension and treated;
•(4) Fasting TG >= 1.70 mmol / L;
•(5) Fasting HDL-C < 1.04 mmol / L;
•Three or more of the above can be used to diagnose metabolic syndrome.
•3. Patients taking atypical antipsychotics had a stable dose for more than 3 months, and their condition was stable, so it was not necessary to adjust the dose of antipsychotics;
•4. Patients aged between 18 and 65 years.

•1. Patients with impulsive, suicidal and self injurious behaviors;
•2. Patients with severe liver and kidney damage, cardiac insufficiency or other acute complications and severe infection;
•3. Co infected patients with alcohol, drugs and other substance abuse;
•4. Patients with other endocrine diseases such as Cushing's syndrome, or Cardiotropic obesity caused by taking a lot of hormones.
•5. Patients with type I diabetes, secondary hypertension and familial dyslipidemia;
•6. Patients who are allergic to Chinese herbal ingredients;
•7. Patients with abnormal laboratory indexes and clinical significance except metabolic syndrome.
•8. Patients during pregnancy and lactation, or those with pregnancy planning within 3 months.

发起方